Back to top
more

Sanofi (SNY)

(Delayed Data from NSDQ)

$55.47 USD

55.47
3,077,855

-0.07 (-0.13%)

Updated Oct 4, 2024 04:00 PM ET

After-Market: $55.48 +0.01 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 19% (47 out of 252)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

3 Biotech Stocks With Rising Earnings Estimates Post Q4

The biotech industry performed reasonably well in Q4. Hence, it is a good idea to select stocks from the sector which saw positive estimate revisions post Q4 earnings release.

    Regeneron and Sanofi Announce Positive Data on Praluent

    Regeneron (REGN) & Sanofi's Praluent achieves the primary endpoint in the ODYSSEY OUTCOMES trial as the drug reduces the overall risk of MACE by 15%.

      Zacks Industry Outlook Highlights: Sanofi, Celgene, Bioverativ, Juno and Merck

      Zacks Industry Outlook Highlights: Sanofi, Celgene, Bioverativ, Juno and Merck

        Biotech Stock Round Up: Regeneron Submits sBLA, Biogen to Withdraw Zinbryta

        The biotech sector was in focus last week with these stories - FDA's acceptance of Regeneron's Dupixent's application for asthma, Biogen and partner AbbVie's decision to withdraw multiple sclerosis drug among others.

          Zacks Industry Outlook Highlights: Sanofi, Celgene, Bioverativ, Juno and Merck

          Zacks Industry Outlook Highlights: Sanofi, Celgene, Bioverativ, Juno and Merck

            FDA Accepts Regeneron/Sanofi's Dupixent sBLA for Asthma

            Regeneron Pharmaceuticals, Inc. (REGN) and partner Sanofi announced that the FDA has accepted the companies' sBLA for Dupixent for asthma with a target date of Oct 20, 2018.

              4 Buy-Ranked Large Cap Pharma Stocks to Boost Your Portfolio

              Though the large-cap pharma sector struggled a little after a strong start in 2018, it is largely expected to rebound as the year progresses.

                Sweta Killa headshot

                Biotech Crushing the Market: Best ETFs & Stocks YTD

                The recent developments are fueling growth in the biotech companies, leading to a rally in their share prices and impressive levels of momentum in biotech ETFs.

                  Emergent (EBS) Q4 Earnings Beat Estimates, 2018 View Solid

                  Emergent's (EBS) earnings and revenues beat estimates in Q4. The top line also improves year over year on higher product sales.

                    BioMarin (BMRN) Q4 Loss Wider Than Expected, Sales Beat

                    BioMarin (BMRN) reports wider-than-expected loss in the fourth quarter of 2017 but beat estimates for sales on higher product revenues.

                      Merck to Buy Australian Firm to Boost Immunotherapy Pipeline

                      Merck (MRK) to buy Australian oncolytic immunotherapies maker Viralytics Limited to strengthen its presence in the fast growing immuno-oncology market.

                        The Zacks Analyst Blog Highlights: ExxonMobil, Caterpillar, Union Pacific, Alexion and Sanofi

                        The Zacks Analyst Blog Highlights: ExxonMobil, Caterpillar, Union Pacific, Alexion and Sanofi

                          Mark Vickery headshot

                          Top Research Reports for ExxonMobil, Caterpillar & Union Pacific

                          Today's Research Daily features new research reports on 16 major stocks, including ExxonMobil (XOM), Caterpillar (CAT) and Union Pacific (UNP).

                            Swarup Gupta headshot

                            Foreign Stock Roundup: TOT, STO & GSK Earnings Impress, BP & SNY Disappoint

                            Global stocks were weighed down by massive losses and heightened volatility on Wall Street last week.

                              Alnylam's (ALNY) Q4 Earnings and Revenues Top Estimates

                              Alnylam Pharmaceuticals (ALNY) reports narrower-than-expected loss and beats sales estimates in the fourth quarter of 2017.

                                Regeneron (REGN) Q4 Earnings & Revenues Top, Eylea Sales Grow

                                Regeneron (REGN) fourth-quarter results were encouraging as the company topped both earnings and sales estimates on the back of Eylea sales.

                                  Biogen Halts Tysabri Development in Stroke as Study Fails

                                  Biogen's Tysabri (natalizumab) falters in a phase IIb study, evaluating it for acute ischemic stroke (AIS) indication.

                                    Sanofi (SNY) Q4 Earnings Lag on Weak Diabetes/Vaccines Sales

                                    Sanofi misses estimates for both earnings and sales in the fourth quarter hurt by continued weakness in the Diabetes franchise and lower vaccine sales. Sanofi looks to return to growth in 2018.

                                      REGN vs. ALXN: Which Stock is Poised for Better Q4 Earnings?

                                      Let's take a look at which of these biotech companies, Alexion (ALXN) or Regeneron (REGN) has an edge ahead of their Q4 release.

                                        Will Regeneron (REGN) Disappoint Investors in Q4 Earnings?

                                        With a mixed track record, we expect investor focus on Regeneron's (REGN) Eylea sales and uptake of Dupixent when it reports Q4 results.

                                          The Zacks Analyst Blog Highlights: Sanofi, Seattle Genetics, AbbVie, Celgene and Vertex

                                          The Zacks Analyst Blog Highlights: Sanofi, Seattle Genetics, AbbVie, Celgene and Vertex

                                            Merck (MRK) Beats on Q4 Earnings, Lags Sales, Guides for '18

                                            Merck (MRK) beats estimates for earnings but misses the same for sales in Q4. Sales of Keytruda remain strong in the quarter.

                                              Amgen (AMGN) Q4 Earnings & Sales Lag, 2018 Sales View Soft

                                              Amgen (AMGN) misses expectations for both earnings and sales and also issues a lower-than-expected sales guidance for 2018. Shares decline in after-hours trading.

                                                Alnylam's (ALNY) RNAi Candidate's NDA Gets Priority Review

                                                Alnylam's NDA for lead candidate patisiran is accepted by the FDA and granted priority review. The FDA also set an action date of Aug 11, 2018.

                                                  Merck vs. Sanofii: Which Stock Is Better Pre-Q4 Earnings?

                                                  With Merck and Sanofi scheduled to report on Feb 2 and Feb 27, respectively, this may be a good time to figure out which of these is a better stock.